
    
      This is a prospective, single masked, comparative, mono-therapeutic trial evaluating three
      fluoroquinolone agents that are approved and marketed for the treatment of conjunctivitis.
      Approximately 120 patients who have corneal ulcers greater than 2 mm but less than 6 mm in
      size who meet all other inclusion criteria will be enrolled into this study. Patients will be
      randomized in a 2:1:1 ratio to receive besifloxacin 0.6% ophthalmic suspension, gatifloxacin
      0.5% ophthalmic solution, or moxifloxacin 0.5% ophthalmic solution.
    
  